Clinical Trials Logo

Esophageal Verrucous Carcinoma clinical trials

View clinical trials related to Esophageal Verrucous Carcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT03584308 Completed - Clinical trials for Papillomavirus Infections

Efficacy of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal

Start date: October 15, 2015
Phase: Phase 2
Study type: Interventional

A randomized, double-blind, phase II clinical trial was conducted versus placebo in 110 patients with esophageal human papillomavirus. The experimental group will receive the VIUSID® plus GLIZIGEN® nutritional supplements, administered on an outpatient basis for 3 months. The control group will receive placebo from Viusid plus Glizigen placebo. It is expected that patients in the experimental group have a 30% higher rate of elimination of the virus than patients in the placebo group after treatment. The study will be conducted in the Superior Digestive Tract consultation of the Institute of Gastroenterology of Havana, Cuba.